CENTRAL PHARMACEUTICALS LIMITED

2-A/1, South-West Darus Salam Road (2nd Floor), Mirpur-1, Dhaka-1216
Phone :+88-02-9038733 Fax: +88-02-9033519
E-mail: info@centralphl.com, Web:www.centralphl.com

HALF YEARLY FINANCIAL STATEMENTS
(UN-AUDITED) as at 31 December 2017

Dear Shareholders,

As per clause No. 17(2) of DSE (Listing) Regulation 2015, we are pleased to enclose the Financial Statements (un-audited) showing, Statement of Financial position, Statement of Comprehensive Income, Statement of Cash Flow and Statement of Changes in Equity for the Half Yearly ended on December 31, 2017.

Un-Audited Statement of Financial Position
s at 31 December, 2017

articulars	31-12-2017 aka	30-06-2017 Taka
SSETS		
on-Current Assets	1,036,502,149	1,056,805,602
roperty, Plant & Equipment	1,036,211,246	1,056,612,218
Intangible Assets	290,903	193,384
urrent Assets	1,281,399,553	1,233,641,390
nventories	411,346,574	434,212,782
Spare Parts & Supplies	35,078,943	41,211,177
Advances, Deposits & Pre-payments	316,756,432	254,953,295
Accounts Receivable	508,764,684	494,605,483
Cash & Bank Balances	9,452,920	8,658,653
otal	2,317,901,702	2,290,446,992
QUITY & LIABILITY		
hareholders' Equity	1,757,848,237	1,740,804,182
hare Capital	1,140,960,425	1,037,236,750
Revaluation Reserve	514,848,089	514,848,089
Retained Earnings	102,039,723	188,719,343
on-Current Liabilities	169,038,274	169,482,920
roject Loan	106,232,789	106,232,789
Deferred Tax Liabilities	62,805,485	63,250,131
urrent Liabilities	391,015,191	380,159,890
hort Term Loan	104,152,185	104,152,185
Sundry Creditors	2,575,754	4,665,427
Liabilities for Expenses	20,721,946	14,416,735
Others Payable	6,582,325	6,582,325
Provision for Tax Liabilitues	248,571,495	243,038,359
Workers' Profit Participation Fund	8,411,486	7,304,859
otal	2,317,901,702	2,290,446,992
et Asset Value (NAV) per Share	15.41	16.78

hairman Director Managing Director Chief Financial Officer Company Secretary

ated: Dhaka
0 January, 2018

Un-Audited Statement of Comprehensive Income
or the half year ended 31 December, 2017

articulars	01-07-2017 to 31-12-2017 (6 months) aka	01-07-2016 to 31-12-2016 (6 months) Taka	01-10-2017 to 31-12-2017 (3 months) Taka	01-10-2016 to 31-12-2016 (3 months) Taka
urnover	135,957,105	273,492,250	55,579,043	210,524,825
ost of Goods Sold	(75,924,750)	(137,091,856)	(31,957,950)	(101,578,228)
ross Profit/(Loss)	60,032,355	136,400,394	23,621,093	108,946,597
perating Expenses	(29,881,223)	(28,207,196)	(17,630,679)	(17,862,962)
dministrative Expenses	(12,442,677)	(7,673,991)	(8,865,784)	(4,417,207)
Selling & Distribution Expenses	(17,438,546)	(20,533,205)	(8,764,895)	(13,445,755)
perating Income	30,151,132	108,193,198	5,990,414	91,083,635
ther Income	-	1,832,495	-	1,832,495
Financial Expenses	(6,911,960)	(3,905,095)	(3,459,160)	(3,905,095)
et Profit/(Loss) before WPPF	23,239,172	106,120,598	2,531,254	89,011,035
ontribution to Workers' Profit Participation Fund	(1,106,627)	(5,265,293)	(120,536)	(4,450,552)
et Profit/(Loss) before Tax	22,132,545	100,855,305	2,410,718	84,560,483
ncome Tax Expenses	(5,088,490)	(25,398,401)	(353,923)	(21,234,909)
urrent Tax	(5,533,136)	(25,213,827)	(602,680)	(21,140,121)
Deferred Tax	444,646	(184,574)	248,757	(94,788)
et Profit/(Loss) after Tax	17,044,055	75,456,904	2,056,795	63,325,574
arning per Share (EPS)	0.15	0.66	0.02	0.56
umber of Shares used to compute EPS	114,096,043	114,096,043	114,096,043	114,096,043

Sd/- Chairman, Sd/- Director, Sd/- Managing Director, Chief Financial Officer, Sd/- Company Secretary

ated: Dhaka
January, 2018

Un-Audited Statement of Changes in Equity
for the half year ended 31 December, 2017

articulars	Share apital	Revaluation Reserve	Retained Earnings	Total
alance as on 01-07-2016	942,942,500	514,848,089	173,927,353	1,631,717,942
Addition of Bonus Share during the year	94,294,250	-	(94,294,250)	-
Addition during the period	-	-	75,456,904	75,456,904
alance as on 31-12-2016	1,037,236,750	514,848,089	155,090,007	1,707,174,846

articulars	Share apital	Revaluation Reserve	Retained Earnings	Total
alance as on 01-07-2017	1,037,236,750	514,848,089	188,719,343	1,740,804,182
Addition of Bonus Share during the year	103,723,675	-	(103,723,675)	
Addition during the period	-	-	17,044,055	17,044,055
alance as on 31-12-2017	1,140,960,425	514,848,089	102,039,723	1,757,848,237

Sd/- Chairman, Sd/- Director, Sd/- Managing Director, Chief Financial Officer, Sd/- Company Secretary

ated: Dhaka
January, 2018

Un-Audited Statement of Cash Flows
for the half year ended 31 December, 2017

articulars	01-07-2017 to 31-12-2017 aka	01-07-2016 to 31-12-2016 Taka
ash Flows from Operating Activities		
ollection from Customers	121,797,904	243,569,330
Payment to Supplier, Employees & Others	(119,971,039)	(233,477,449)
et Cash Generated from Operating Activities	1,826,865	10,091,881
ash Flows from Investing Activities		
cquisition of Property, Plant & Equipment	(1,025,768)	(3,565,783)
et Cash used in Investing Activities	(1,025,768)	(3,565,783)
ash Flows from Financing Activities		
roject Loan	-	-
Short Term Loan from/(Repayment)	-	-
Bank Interest & Charges Paid	(6,830)	(27,516)
et Cash Generated from Financing Activities	(6,830)	(27,516)
et Cash Increase in Cash & Cash Equivalents	794,267	6,498,582
ash & Cash Equivalents at the Beginning	8,658,653	9,929,674
ash & Cash Equivalents at the End	9,452,920	16,428,256
et Operating Cash Flows per Share (NOCFPS)	0.02	0.09

Sd/- Chairman, Sd/- Director, Sd/- Managing Director, Chief Financial Officer, Sd/- Company Secretary

ated: Dhaka
January, 2018

Notes to the Interim Financial Statements
for the half year ended 31 December, 2017

.00 Reporting Entity:

he Company was incorporated in 13 November, 1980 as a 'Private' Company limited by shares and registered with the Registrar of Joint Stock Companies & Firms of Bangladesh under the Companies Act, 1913 vide Registration No. C-8514(353). On 20 December, 2010 the Company registered itself as a Public Limited Company under the Companies, Act 1994. The Company is listed with both Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) at 22 July, 2013 and 15 July, 2013 respectively and trading of the share of the Company has been started from 14 August, 2013.

he registered and corporate office of the Company is located in its own premises at 2A/1, South-West Darus Salam Road (2nd Floor), Mirpur-1, Dhaka-1216 and its factory is situated in its own premises at 2A/1, South-West Darus Salam Road, Mirpur-1, Dhaka-1216.

he principal activities of the Company throughout the year continued to be manufacturing and marketing of quality medicine.

.00 Basis of Preparation of the interim Financial Statements:

hese financial statements are the un-audited interim financial statements (here after 'the interim financial statements') of Central Pharmaceuticals Ltd., incorporated in Bangladesh under the Companies Act, 1994 for the 2nd quarter ended on 31 December, 2017 (here after 'the interim period'). They are prepared in accordance with the Bangladesh Accounting Standard (BAS-34) 'Interim Financial Reporting'. These financial statements should read in conjunction with the Annual Financial Statements as of 30 June, 2017, as they provided an update of previously reported information.

he accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

he company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

ncome Tax expense is recognized based upon the best estimate of the weighted average income tax expected for the reporting period.

he company has no reportable operating segments as per IFRS-8.

here is no significant event after the end of the interim period that has to be reflected in the financial statements for the interim period.

Note: The Half Yearly Financial Statement (Un-audited) as of 31 December 2017 are Available in the website of the Company. The address of the website is www.centralphl.com